Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations by Ma, J. (Jianguo) et al.
Cancer Chemother Pharmacol (1996) 38: 391—394 ( Springer-Verlag 1996
SHORT COMMUNICATION
Jianguo Ma · Gerrit Stoter · Jaap Verweij
Jan H.M. Schellens
Comparison of ethanol plasma-protein precipitation with plasma
ultra®ltration and trichloroacetic acid protein precipitation
for the measurement of unbound platinum concentrations
Received: 23 September 1995 /Accepted: 17 January 1996
Abstract Sample preparation for the measurement of
non-protein-bound platinum was evaluated by precipi-
tation of plasma proteins with cold ethanol. The
method was compared with the routinely used plasma
ultrafiltration and with trichloroacetic acid (TCA) pro-
tein precipitation. After incubation of human plasma
samples with cisplatin or carboplatin, unbound plati-
num concentrations were determined applying Amicon
Diaflo ultrafiltration membranes and Millipore ultra-
free-MC filters. For protein precipitation, 1 ml of cold
(!20 °C) pure ethanol was added to 0.5 ml of human
plasma and the supernatant was collected after 2 h, or
0.5 ml of cold 20% TCA was added to 0.5 ml of plasma.
Platinum was analyzed by atomic absorption spectro-
photometry (AAS). There was no significant difference
between the ethanol and ultrafiltration methods in the
unbound platinum concentration. The protien content
in the supernatant (1.00$0.20%) was slightly higher
than that in the Amicon (0.58$0.05%) and Millipore
(0.55$0.04%) ultrafiltrates. On average, the TCA and
ethanol method seemed to be equally appropriate. The
ethanol precipitation method is concluded to be simple,
convenient, and reproducible and has negligible costs.
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Introduction
Quantitation of the unbound, i.e., non-protein-bound,
plasma concentration of platinum is important for de-
termination of the phramacokinetics of the platinum
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drugs cisplatin and carboplatin. Only the unbound
concentration of the drug is likely to be pharmacolo-
gically active. After intravenous administration, cis-
platin and carboplatin become tightly bound to plasma
proteins and other tissue components. Previous studies
have revealed that the binding to plasma proteins is
covalent and almost irreversible [3, 4]. Due to its high
reactivity the binding of cisplatin to plasma proteins is
very rapid, whereas the rate of binding of carboplatin is
much lower [9, 10, 23, 24]. Plasma ultrafiltration for
the measurement of unbound platinum applying ultra-
filtration tubes is routinely used for this assay [2, 6, 7, 9,
11, 16, 17, 23]. Mostly a cutoff level for the filtration
membranes of 30, 000 Da is used. It has previously been
suggested that precipitation of plasma proteins with
cold ethanol may be a good alternative to the ultrafil-
tration of plasma for measurement of unbound plati-
num [13, 18]. In addition, trichloroacetic acid (TCA)
has been used to measure unbound platinum [8, 21, 22,
25]. Herein we report on experiments in which the
ethanol precipitation method was validated and com-
pared with the results obtained with two ultrafiltration
systems and the TCA precipitation method.
Subjects and methods
Cisplatin was obtained from Lederle (Wolfratshausen, Germany)
and carboplatin, from Pharmachemie (Haarlem, The Netherlands).
Amicon Diaflo ultrafiltration membranes (cutoff level 30, 000 Da)
and the MAPS-1 Starter Kit were obtained from Amicon (Beverly,
Mass. USA), and Millipore filters (ultrafree-MC millipore cutoff
level 30, 000 Da) were obtained from Millipore (Bedford, Mass.,
USA). The atomic absorption spectrophotometer (AAS) was
a Perkin-Elmer 3030B device (Uberlingen, Germany). Triton X-100
was obtained from Baker (Deventer, The Netherlands), and cesium
chloride (CsCl) and absolute ethanol (analytical grade, Merck prod-
uct 983, 99.8%) were supplied by Merck (Darmstadt, Germany). All
other chemicals were obtained from Baker Deventer, The Nether-
lands) and were of analytical grade.
Whole-blood samples of 20 ml were obtained from four healthy
volunteers and plasma was collected. In addition, plasma samples
were used from 11 patients with solid tumors who were being treated
with cisplatin in an ongoing phase II and pharmacology study for
which approval was obtained from the local ethics committee.
Of the plasma obtained from the four volunteers, 10 ml was
incubated with cisplatin at 5 lg/ml or with carboplatin at 50 lg/ml
at 37 °C for 24 h. Immediately and at 1, 2, 4, and 24 h after addition
of the platinum drug, three plasma aliquots were taken and used for
ultrafiltration at 4 °C and 1, 000 g for 30 min or for the addition of
2 vol. of cold (!20 °C) ethanol (99.8% absolute). The latter sample
was mixed on a whirl mixer for 10 s and subsequently stored at
!20 °C for 4 h. The sample was then centrifuged at 4 °C and 4, 000 g
for 10 min and the supernatant was carefully transferred to a clean
2-ml Eppendorf tube and stored at !20 °C until analysis. Total and
unbound platinum were analyzed after dilution (total platinum with
0.2% Triton X-100 and 0.06% CsCl, and unbound platinum with
deionized H
2
O). The protein contents of the plasma samples prior to
treatment and of the samples obtained after ultrafiltration and
protein precipitation were determined by the Lowry method [14].
Also, TCA precipitation of plasma protein was compared with the
ethanol method as well as with ultrafiltration. On a second occasion,
20 ml of whole blood was collected from the same volunteers and
used for incubation of plasma with cisplatin and carboplatin. The
periods of incubation were 1 and 24 h. An equal volume of cold 20%
TCA was added to 0.5 ml of plasma, and the mixture was shaken on
a whirl mixer and put on ice for 10 min as described by Siddik et al.
[22]. The other assays were carried out as described above. All
assays were carried out at least in triplicate.
The period of storage of the ethanol-treated sample at !20 °C
prior to collection of the supernatant was varied to study the
influence of storage on the remaining protein content and unbound
platinum recovery in the supernatant. Four 5-ml plasma samples
were treated with cisplatin as outlined above and stored at !20 °C.
Aliquots were taken at 0, 1, 2, 4, and 16 (overnight) h after storage
and treated as described above.
Unbound platinum concentrations were also determined in the
plasma of 11 patients who were being treated with a 70-mg/m2 dose
of cisplatin given on a weekly schedule by 3-h infusion. A 4-ml
volume of whole blood was taken at 0.5 and 3 h after the end of the
cisplatin infusion and was immediately processed according to the
outlined ultrafiltration and ethanol precipitation methods. Students
two-sided t-test was used to evaluate differences between the treat-
ment methods.
Results
The concentration of unbound platinum detected in the
Amicon ultrafiltrate immediately after the addition
of cisplatin to plasma was 2.71$0.08 lg/ml, that
measured in the Millipore ultrafiltrate was
2.83$0.31 lg/ml, and that determined in the super-
natant after ethanol treatment was 2.79$0.08 lg/ml
[n"3, not significant (NS)]. After carboplatin addi-
tion the concentrations were 26.51$1.24 (Amicon),
27.64$1.02 (Millipore), and 27.53$1.4 (ethanol; NS).
The variation coefficient obtained with the ethanol
method was lower or of the same order as that obtained
with the ultrafiltration methods (Fig. 1). The concentra-
tions of the total platinum detected in the plasma
samples were 3.07$0.12 lg/ml after incubation with
cisplatin and 25.14$0.75 lg/ml after incubation with
carboplatin. The recovery of unbound platinum in the
ultrafiltrates and supernatant after ethanol precipita-
tion is given in Table 1. The protein content of the
samples after ultrafiltration or ethanol precipitation is
also given in Table 1. The amount of protein measured
Fig. 1 A Unbound platinum concentrations determined in plasma
supernatants (black bars, cold ethanol protein precipitation) and in
plasma ultrafiltrates using Millipore (white bars) and Amicon (dotted
bars) ultrafiltrates. Plasma samples were incubated with cisplatin at
5 lg/ml in vitro and analyzed at different time points after the start
of the incubation. On a second occasion the in vitro incubation
experiments were repeated using plasma from the same volunteers,
which was incubated for 1 (1*) and 24 h (24*) with cisplatin. The
TCA method (hatched bars) was compared with the other three
methods. B Unbound platinum concentrations determined in
plasma supernants (black bars, cold ethanol protein precipitation)
and in plasma ultrafiltrates using Millipore (white bars) and Amicon
(dotted bars) ultrafiltrates. Plasma samples were incubated with
carboplatin at 50 lg/ml in vitro and analyzed at different time
points after the start of the incubation. On a second occasion the in
vitro incubation experiments were repeated using plasma from the
same volunteers, which was incubated for 1 (1*) and 24 h (24*) with
carboplatin. The TCA method (hatched bars) was compared with the
other three methods. `P(0.05 as compared with the other three
methods
in the supernatant after ethanol protein precipitation
was slightly, albeit significantly, higher than that found
in the ultrafiltrates.
Immediate collection of the supernatant after the
addition of cold ethanol to plasma and vortexing re-
sulted in a higher amount of remaining protein (2%)
and in higher platinum recovery (5—10%). After 2 h of
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Table 1 Comparison of three plasma pretreatment methods for
measurement of unbound platinum (CDDP cisplatin, CBDCA car-
boplatin)!
Method Unbound Pt Unbound Pt Remaining
recovery (%) recovery (%) protein
(CDDP) (CBDCA) (%)
Millipore 92$10 110$1 0.58$0.05
filter
Ethanol 91$6 109$4 1.00$0.20*
precipitation
Amicon 88$3 105$2 0.55$0.04
filter
*P(0.05 as compared with Millipore and Amicon
!Data represent mean values $SD (n’3)
storage at !20°C the amount of protein decreased to
1%, which did not decrease further upon longer stor-
age. A total of four Millipore filters were needed to
obtain the same volume of ultrafiltrate acquired with
one Amicon unit. With one Millipore filter a 10- ll
volume of ultrafiltrate could be obtained. Analysis of
the Amicon and Millipore ultrafiltrates resulted in
much higher background signals on the AAS as com-
pared with the supernatant after ethanol protein pre-
cipitation.
The concentrations of unbound platinum measured
after incubation with cisplatin for 1 h were slightly
(12%), albeit significantly, higher after TCA protein
precipitation (Fig. 1A). At 24 h after incubation there
was no significant difference between any of the four
methods. After incubation with carboplatin, no signifi-
cant difference in unbound platinum concentrations
was observed (Fig. 1B). The concentrations of unbound
platinum detected in the patients’ samples at 0.5 h after
the end of the cisplatin infusion were 568$182
(ethanol), 561$231 (Millipore), and 511$198 ng/ml
(Amicon; n"11, NS). At 3 h post-infusion the concen-
trations were 69$17 (ethanol), 74$19 (Millipore),
and 68$17 ng/ml (Amicon; n"11, NS).
Discussion
Measurement of the unbound platinum concentration
after treatment with cisplatin and carboplatin is essen-
tial for assessment of the pharmacokinetics of these
drugs [1, 15, 19, 23]. Previous studies have revealed
significant relationships between the area under the
platinum plasma concentration-time curve (AUC) and
the likelihood of tumor response and toxicity [1, 5, 12,
15, 19, 20]. The results of the present study illustrate
that treatment of plasma with cold ethanol to precipi-
tate proteins is adequate for preparation of the sample
for the measurement of non-protein-bound platinum.
A comparison of this technique with the routinely used
ultrafiltration methods revealed that the recovery of
unbound platinum observed for ethanol treated sam-
ples was not significantly different from that recorded
for the Amicon and Millipore ultrafiltrates. The per-
centage of protein remaining in the supernatant after
ethanol protein precipitation was slightly higher than
that remaining in the ultrafiltrates. The magnitude of
the difference seems to be unimportant, because the
recovery was not significantly different from that re-
corded for the ultrafiltration method. The concentra-
tion of unbound platinum detected in the samples of
patients who were being treated with cisplatin also
showed no difference between the three methods. The
recovery of platinum after the addition of cisplatin in
vitro is slightly lower than 100% (Table 1). The most
plausible explanation for this is that during sample
workup the binding process of cisplatin to plasma
proteins continues. The recovery of carboplatin was
slightly higher than 100% for all methods.
The TCA method resulted in a slightly higher un-
bound platinum concentration after incubation of
plasma for 1 h with cisplatin. This was similar to the
result obtained when plasma supernatant was immedi-
ately collected by the ethanol precipitation method.
This could be explained by partly reversible binding of
cisplatin or incomplete precipitation of proteins. An-
other possibility would be that during the longer
sample workup involved in the other three methods,
cisplatin plasma-protein binding continues, thereby
leading to an underestimation of the unbound concen-
tration. No significant difference was obtained with
carboplatin, although the percentage bound was much
lower than that recorded for cisplatin. The result is in
contrast with previously published data [22]. However,
in that study another species was evaluated and the
binding kinetics of carboplatin were found to be much
faster than they were in the present study. On average,
the TCA method and the ethanol method seem to be
equally appropriate.
The optimal period of storage for the ethanol-treated
sample at !20°C appears to be 2 h. After that time, no
further decrease in the amount of protein remaining
could be observed. The yield of ultrafiltrate noted for
the Millipore filters was only one-quarter of the
amount obtained with the Amicon filters. The back-
ground signal on the AAS was lowest for the ethanol
method, indicating that the sample was relatively clean
as compared with the ultrafiltrates. This may be benefi-
cial in cases of very low plasma concentrations. Cold
ethanol precipitation of plasma proteins is a simple,
practical, reproducible, and extremely inexpensive
method for preparation of samples for the measure-
ment of unbound platinum.
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